Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Filtrar os resultados da pesquisa
Selecionar modelos de dados

Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

34 Resultados da pesquisa.

CDASH Concomitant Medication - Concomitant medication

- 20/06/2018 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 2 Idiomas

Grupos de itens: General information, Details

translated and modified from CDASH 2011-10-24 http://www.cdisc.org

60 DAYS POST-TREATMENT CONCOMITANT MEDICATIONS Roche H0650g Breast Cancer - 60 DAYS POST-TREATMENT CONCOMITANT MEDICATIONS

- 15/03/2021 - 1 Formulário, 1 Grupo de itens, 11 Elementos de dados, 1 Idioma

Grupo de itens: CONCOMITANT MEDICATIONS

Study part: 60 Days Post- Treatment Concomitant medications. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

CONCOMITANT MEDICATIONS Roche H0650g Breast Cancer - CONCOMITANT MEDICATIONS

- 15/03/2021 - 1 Formulário, 1 Grupo de itens, 11 Elementos de dados, 1 Idioma

Grupo de itens: CONCOMITANT MEDICATIONS

Study part: Concomitant medications. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

PREVIOUS/ CONCOMITANT MEDICATIONS Roche H0650g Breast Cancer - PREVIOUS/ CONCOMITANT MEDICATIONS

- 15/03/2021 - 1 Formulário, 1 Grupo de itens, 10 Elementos de dados, 1 Idioma

Grupo de itens: CONCOMITANT MEDICATIONS

Study part: Previous/ Concomitant medications. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Determination of starting dose and up-titration regimen for a new formulation of Ropinirole in healthy adults, 101468/201 - Concomitant Medication

- 10/05/2019 - 1 Formulário, 2 Grupos de itens, 11 Elementos de dados, 1 Idioma

Grupos de itens: Administrative Data, Concomitant Medication

Study ID: 101468/201 Clinical Study ID: 101468/201 Study Title: A Single Blind, Parallel Group, Up-titration, Phase 1 Study in Healthy Volunteers to Determine a Starting Dose and Select an Up-titration Regimen for a new Formulation of Ropinirole Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Restless Legs Syndrome The Study consists of 21 Visits(Days): Screening (at least 21 days before dosing) Week 1: including Day 1-7 Week 2: including Day 8-14 Week 3: including Day 15-19 Follow-up Visit (7-14 days after last dose) This document contains the concomitant medication form. It has to be filled in if the subject takes concomitant medication during the study.

Concomitant Medications Month 1- 3 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Concomitant Medications Month 1- 3

- 18/02/2018 - 1 Formulário, 1 Grupo de itens, 11 Elementos de dados, 1 Idioma

Grupo de itens: Concomitant Medications

Study part: Concomitant Medications Month 1- 3. A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Concomitant Medications Screening rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2598g - Concomitant Medications Screening

- 18/02/2018 - 1 Formulário, 1 Grupo de itens, 11 Elementos de dados, 1 Idioma

Grupo de itens: Concomitant Medications

Study part: Concomitant Medications Screening . A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) In Subjects With Minimally Classic Or Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Concomitant Medications Month 10- 12 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Month 10- 12

- 04/02/2018 - 1 Formulário, 1 Grupo de itens, 12 Elementos de dados, 1 Idioma

Grupo de itens: Concomitant Medications

Study part: Concomitant Medications Month 10- 12. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Concomitant Medications Month 7- 9 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Month 7- 9

- 24/01/2018 - 1 Formulário, 1 Grupo de itens, 12 Elementos de dados, 1 Idioma

Grupo de itens: Concomitant Medications

Study part: Concomitant Medications Month 7- 9. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Concomitant Medications Month 4- 6 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Month 4- 6

- 22/01/2018 - 1 Formulário, 1 Grupo de itens, 12 Elementos de dados, 1 Idioma

Grupo de itens: Concomitant Medications

Study part: Concomitant Medications Month 4- 6. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Concomitant Medications Month 1- 3 rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Month 1- 3

- 21/01/2018 - 1 Formulário, 1 Grupo de itens, 12 Elementos de dados, 1 Idioma

Grupo de itens: Concomitant Medications

Study part: Concomitant Medications Month 1- 3. A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Concomitant Medications Screening rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g - Concomitant Medications Screening

- 14/01/2018 - 1 Formulário, 1 Grupo de itens, 11 Elementos de dados, 1 Idioma

Grupo de itens: Concomitant Medications

Study part: Concomitant Medications Screening . A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.